Table 2.
The number of registered trials on GSL-rich foods and extracts or pure compounds, according to their characteristics.
| Foods (n = 27) | Extracts or Pure Compounds (n = 60) | |
|---|---|---|
| Goal | ||
| Health effects | 18 | 47 |
| Bioavailability | 8 | 6 |
| Both | 1 | 7 |
| Duration | ||
| Acute | 8 | 2 |
| Chronic | 18 | 55 |
| Both | 1 | 3 |
| Subjects | ||
| Healthy | 17 | 24 |
| Subjects with risk factors | 3 | 2 |
| Patients | 7 | 34 |
| Primary outcome | ||
| Cardiovascular risk markers | 1 | 1 |
| Glucose and insulin parameters | 0 | 2 |
| Vascular and endothelial function | 0 | 2 |
| Cognitive function | 0 | 15 |
| Inflammation | 5 | 2 |
| Gut microbiota | 2 | 0 |
| Safety and tolerability | 1 | 5 |
| Detoxification | 2 | 9 |
| Blood GSLs concentration | 4 | 4 |
| Urinary GSLs concentration | 7 | 8 |
| Cancer | 4 | 11 |
| Oxidative stress | 0 | 4 |
| Skin health markers | 0 | 3 |
| Other | 7 | 5 |
| Location | ||
| United States of America | 14 | 37 |
| United Kingdom | 10 | 6 |
| China | 0 | 11 |
| Sweden | 0 | 3 |
| Spain | 2 | 0 |
| Portugal | 1 | 0 |
| Brazil | 0 | 1 |
| Denmark | 0 | 1 |
| Japan | 0 | 1 |
GSLs, glucosinolates.